NRG5051
ALS/MND and Parkinson's Disease
Phase 1Active
Key Facts
About NRG Therapeutics
NRG Therapeutics is an innovative, privately held biotech founded in 2018, advancing a pipeline of CNS-penetrant small molecules that inhibit the mitochondrial permeability transition pore (mPTP). The company reached a key milestone in 2026 by initiating a first-in-human Phase 1 trial for its lead candidate, NRG5051, positioning it as a clinical-stage entity. With a focus on ALS and Parkinson's, NRG aims to address significant unmet medical need through a novel mechanism of action targeting a fundamental driver of neurodegeneration. The company benefits from experienced founders, leadership, and specialized investors in the neuroscience space.
View full company profile